Back

The DIALY-MRA trial: a randomised comparison of finerenone versus spironolactone in patients on maintenance dialysis - a 3-month biomarker and safety study

28 August 2026 (11:35 - 11:45)
Organised by: Logo
Congress Presentation Part of: Cardiorenal interactions in chronic kidney disease: biomarkers, education, and heart failure outcomes Renal Failure and Cardiovascular Disease ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Rafael Rascon Sabido

Mexican Institute of Social Security (IMSS), Veracruz (Mexico)

5 More presentations in this session

Presentation thumbnail
Erythritol and xylitol predict mortality, cardiovascular events, and kidney disease progression in chronic kidney disease: insights from the GCKD study
Doctor A. Thiele (Berlin, DE)
Abstract Slides Video
Presentation thumbnail
Cardio–renal–metabolic integrated education for patients with heart failure, type 2 diabetes and chronic kidney disease: a pragmatic controlled cohort study
Doctor F. Khan (Peshawar, PK)
Abstract Slides Video
Presentation thumbnail
Differences in outcomes according to the type of heart failure and kidney disease stages in patients with heart failure and chronic kidney disease
Doctor M. Anguita Gamez (Madrid, ES)
Abstract Slides Video
Presentation thumbnail
Impact of CKD severity and protective effect of hemodialysis on cardiovascular events in patients who underwent PCI: insights from the CLIDAS-PCI database
Doctor G. Mizokami (Fukuoka, JP)
Abstract Slides Video
Presentation thumbnail
Sex-specific predictors and prognosis of chronic kidney disease in heart failure - insights from the CardioMining study
Doctor K. Barmpagiannos (Oklahoma City, US)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiorenal interactions in chronic kidney disease: biomarkers, education, and heart failure outcomes
Video

The Event

Event poster

ESC Congress 2026

28 August 2026 11:35 CET
You may be interested in
thumbnail
Congress Presentation
Deep dive and Q&A: unraveling the differences between MRAs for the treatment of heart and kidney disease. Join a conversation discussing key evidence!
19 May 2025
thumbnail
Congress Session
HOT LINE SESSION 8
29 August 2022
thumbnail
Congress Presentation
Cardiovascular and survival outcomes associated with spironolactone use in dialysis-dependent heart failure
9 May 2026
thumbnail
Congress Presentation
Novedades terapéuticas en el paciente cardiorrenal.
22 May 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources